Purtal.guardanthealth.com

Guardant Health Statement on Biden-Harris Administration’s …

WEBREDWOOD CITY, Calif. – February 4, 2022 – Guardant Health stands with the Biden-Harris Administration’s renewed commitment to the Cancer Moonshot and its goal to reduce the death rate from cancer by at least 50 percent over the next 25 years – and we believe this goal is achievable.

Actived: 5 days ago

URL: https://purtal.guardanthealth.com/2022/02/04/guardant-health-statement-on-biden-harris-administrations-renewed-commitment-to-the-cancer-moonshot/

Catching cancer extremely early

WEBAn electrical engineer and one of Guardant Health’s co-founders and president, AmirAli Talasaz, says that they’ve tested blood samples from more than 150,000 patients and “looked at tumor DNA shed from solid tumors.”. From this work, Guardant Health has recently introduced a test for early-stage colorectal cancer.

Category:  Cancer Go Health

Guardant Health to Showcase New Data at San Antonio Breast …

WEBPresentations to highlight role of Guardant liquid biopsy tests and real-world data to help identify actionable biomarkers, co-occurring mutations and molecular response to therapy

Category:  Health Go Health

Guardant Health Receives Medicare Coverage for Guardant …

WEBFirst blood-only liquid biopsy test for molecular residual disease testing now covered for certain fee-for-service Medicare patients in US with stage II or III colorectal cancer

Category:  Cancer Go Health

Guardant Health and Susan G. Komen® Partner to Develop …

WEBCollaboration will help researchers understand value of monitoring breast cancer patients for residual or recurring disease with Guardant Reveal™ blood test.

Category:  Cancer Go Health

Biopharma Solutions

WEBHarnessing the power of epigenomics for precision oncology Epigenetic changes have a tremendous impact on cancer development and progression, yet epigenomic biomarkers

Category:  Cancer Go Health

Guardant360® CDx liquid biopsy is helping to bring the …

WEBGuardant360® CDx liquid biopsy is helping to bring the promise of precision oncology to more advanced cancer patients Comprehensive genomic profiling (CGP), also known as biomarker testing, genotyping, or tumor profiling, is a test

Category:  Cancer Go Health

Guardant Health Appoints Myrtle Potter to Its Board of Directors

WEBFor Biopharma. For Employers. Products. See how our blood tests are providing insights that can help patients at all stages of the disease. Shield™Blood Test. Guardant Complete Portfolio. Biopharma Solutions. Clinical Studies. View all of our screening, early-stage cancer, and advanced cancer clinical studies.

Category:  Cancer Go Health

Guardant Health Initiates ORACLE Study to Evaluate Performance …

WEB1,000-patient prospective study in 11 solid tumors will monitor ctDNA levels up to five years

Category:  Health Go Health

CANCER WELLNESS PROGRAM FACT SHEET PROSTATE CANCER

WEBWhat you need to know. Prostate is the 2nd most common cancer in men. 90% of prostate cancer is slow growing but aggresive forms can be dangerous. Genetic testing can improve prostate cancer treatment and diagnosis. Screening can start at 40 to 50 yrs old depending on risk and family history. cancer is slow growing & local. & can spread.

Category:  Cancer Go Health

Debunking 5 Myths Associated with Blood-Based Cancer Screening

WEBCancer screening tests are very different from hereditary cancer tests. To understand this clearly, we first need to understand the difference between a screening test and a diagnostic test. A screening test is usually done to detect diseases in individuals who do not have any symptoms.

Category:  Cancer Go Health

Using Kmerizer, a germline and somatic genotyper for …

WEBUsing Kmerizer, a germline and somatic genotyper for immune associated complex alleles in GuardantINFINITY, for immunotherapy response prediction using cfDNA

Category:  Health Go Health

Lindsey Cotton, D.O. Med., MS, Global Medical Affairs, Guardant …

WEBLindsey Cotton joined Guardant Health with over 20 years of medical experience. She began her medical career at Columbia St. Mary’s Hospital

Category:  Medical Go Health

What Why How When

WEBLUNG CANCER What you need to know. CANCER WELLNESS PROGRAM FACT SHEET • All cancer is genetic, it is always caused by changes to DNA. • The DNA changes in the cancer itself can help guide

Category:  Cancer Go Health

New Guardant360 Response™ blood test offers oncologists …

WEBBy using the Guardant360 Response test together with the Guardant360 CDx test, oncologists now have an optimized solution from treatment selection to treatment response monitoring

Category:  Health Go Health

What Why How When

WEBSKIN CANCER What you need to know. CANCER WELLNESS PROGRAM FACT SHEET • All cancer is genetic, it is always caused by changes to DNA. • The DNA changes in the cancer itself can help guide

Category:  Cancer Go Health

November 1, 2022 The Office of Management and Budget …

WEBreviews each year.”2 Furthermore, in response to a Congressional inquiry, the Director of AHRQ indicated that the USPSTF could complete more reviews and modify its processes to be more nimble and better adapt to medical advancements if the funding level for its …

Category:  Medical Go Health

Abstract Methods

WEBMethods Abstract Liquid biopsy offers a rapid and non-invasive alternative to tissue biopsy for identifying biomarkers. More recently, its application has broadened to include assessment of early response to therapy (i.e. molecular

Category:  Health Go Health